Serum Institute of India makes strategic investment in IntegriMedical
The Serum Institute of India (SII), has announced a strategic investment in IntegriMedical, acquiring a 20% stake in the company. This collaboration aims to advance the development and deployment of Needle-Free Injection System (N-FIS) technology.
This partnership aligns with SII’s vision of ‘Health for
All’ and IntegriMedical’s mission to ‘Transform Healthcare Globally.’ Together,
they aim to provide patient comfort, increase compliance, reduce needle-stick
injuries, and enhance the efficacy of liquid medications via needle-free
dispersion.
IntegriMedical has developed a US-patented Needle-Free Injection System that uses a
high-velocity jet stream powered mechanically to administer biologics and drugs
effectively. This innovative drug delivery solution aims to alleviate pain
during administration, providing needle-phobic patients with a stress-free
experience.
Comments
Post a Comment